

CSD/BSE&NSE/BM&TW/2022-23

June 24th, 2022

To
The General Manager
Listing Department
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 530239

Scrip Symbol: SUVEN

Dear Sir/Madam,

Sub: Outcome of Board Meeting dated 24th June, 2022 of Suven Life Sciences Limited (the “Company”) under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“SEBI LODR Regulations”)

.....

With reference to the above subject and in accordance with the provisions of Regulation 30 of the SEBI LODR Regulations we wish to inform you that the board of directors (“**Board**”) of the Company at their meeting held today, i.e. 24th June, 2022 approved the following along with other business matters:

- 1) Approved the raising of funds, through issuance and allotment of equity shares having face value of ₹ 1 each up to an aggregate amount of ₹ 400 Crores (Rupees Four Hundred Crores) on rights basis and on such terms (as decided by the Board or a duly constituted committee of the Board, at a later date) to the eligible equity shareholders of the Company, as on the record date (to be notified subsequently), subject to receipt of regulatory/ statutory approvals, in accordance with the applicable laws including the provisions of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, SEBI LODR Regulations and the Companies Act, 2013, and rules and regulations made thereunder, each as amended from time to time and approved other related matters including the constitution of a Rights Issue Committee to implement the proposal of Rights Issue.
- 2) The Board of Directors has considered and approved increase in the Authorized Share Capital from Rs. 20 crores divided into 20 crores equity shares of Rs. 1/- each to Rs. 30 crores divided into 30 crores equity shares of Rs. 1/- each and consequential alteration in the Memorandum of Association of the Company, subject to the approval of shareholders of the Company.

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com

The meeting commenced at 11:00 a.m. and concluded at 11:55 a.m.

We request you to take the above same on your record.

Thanking you,
Yours faithfully,

For **Suven Life Sciences Limited**



Shrenik Soni

Company Secretary & Compliance Officer

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com